Jasper Therapeutics Inc. (JSPR)
Jasper Therapeutics Statistics
Share Statistics
Jasper Therapeutics has 15.02M shares outstanding. The number of shares has increased by -0.42% in one year.
Shares Outstanding | 15.02M |
Shares Change (YoY) | -0.42% |
Shares Change (QoQ) | 0.14% |
Owned by Institutions (%) | 68.35% |
Shares Floating | 11.88M |
Failed to Deliver (FTD) Shares | 30 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.22M, so 21.43% of the outstanding shares have been sold short.
Short Interest | 3.22M |
Short % of Shares Out | 21.43% |
Short % of Float | 28.62% |
Short Ratio (days to cover) | 3.88 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -1.15. Jasper Therapeutics's PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -1.15 |
PS Ratio | 0 |
Forward PS | 0.4 |
PB Ratio | 5.06 |
P/FCF Ratio | -4.94 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Jasper Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.03.
Current Ratio | 4.98 |
Quick Ratio | 4.98 |
Debt / Equity | 0.03 |
Debt / EBITDA | -0.02 |
Debt / FCF | -0.03 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $0 |
Employee Count | 64 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -84.35% in the last 52 weeks. The beta is 2.24, so Jasper Therapeutics's price volatility has been higher than the market average.
Beta | 2.24 |
52-Week Price Change | -84.35% |
50-Day Moving Average | 5.59 |
200-Day Moving Average | 16.2 |
Relative Strength Index (RSI) | 29.07 |
Average Volume (20 Days) | 551.1K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -76.24M |
Net Income | 0 |
EBITDA | -76.24M |
EBIT | n/a |
Earnings Per Share (EPS) | -4.89 |
Balance Sheet
The company has 71.64M in cash and 1.81M in debt, giving a net cash position of 69.82M.
Cash & Cash Equivalents | 71.64M |
Total Debt | 1.81M |
Net Cash | 69.82M |
Retained Earnings | -240.87M |
Total Assets | 79.9M |
Working Capital | 60.57M |
Cash Flow
In the last 12 months, operating cash flow was -62.6M and capital expenditures -552K, giving a free cash flow of -63.15M.
Operating Cash Flow | -62.6M |
Capital Expenditures | -552K |
Free Cash Flow | -63.15M |
FCF Per Share | -4.33 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
JSPR does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for JSPR is $64, which is 1409.4% higher than the current price. The consensus rating is "Buy".
Price Target | $64 |
Price Target Difference | 1409.4% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Stock Splits
The last stock split was on Jan 4, 2024. It was a backward split with a ratio of 1:10.
Last Split Date | Jan 4, 2024 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -1.33 |
Piotroski F-Score | 0 |